Floatz logo

rac-(2R)-(9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid

Pancreatic Cancer

Ability Pharmaceuticals SLSmall moleculePhase 1/2Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
59/ 100

Competitive context

382 Active assets in the Pancreatic Cancer cohort.

Asset / SponsorPhaseRating
Tinzaparin
Helsinki University Central Hospital
Phase 4BBB
FLUOROURACILUM
Memorial Sloan Kettering Cancer Center
Phase 3BB
Eloxatin
Memorial Sloan Kettering Cancer Center
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Taiho Oncology, Inc.
Phase 3BB
Irinotecan
Memorial Sloan Kettering Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

rac-(2R)-(9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid is also rated in:

squamous cell lung carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
endometrial carcinomaDormant
CC
Indicative ·
44 / 100
View asset →
cancerDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →